

Cho S¹, Choi H², Bae J H², Oh C Y³, Kim J C⁴, Jeong S⁵, Choi J B⁶, Lee D H⁷, Ko W J⁸, Seo J T⁹, Lee K W¹⁰, Kim Y H¹⁰

1. Department of urology, Inje University, Ilsanpaik Hospital, Goyang, Korea, **2.** Department of urology, Korea University, Ansan Hospital, Ansan, Korea, **3.** Department of Urology, Hallym University College of Medicine, Chuncheon, Korea, **4.** Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea, **5.** Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea, **6.** Department of Urology, Ajou University School of Medicine, Suwon, Korea, **7.** Department of Urology, Incheon St. Mary's Hospital, The Catholic University College of Medicine, Incheon, Korea, **8.** Department of Urology, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea, **9.** Department of Urology, Cheil General Hospital & Women's Healthcare Center, Catholic Kwandong University College of Medicine, Seoul, Korea, **10.** Department of Urology, Soonchunhyang University College of Medicine, Cheonan, Korea

DIFFERENCES IN THE CLINICAL EFFICACY OF SOLIFENACIN TO MANAGE THE DIABETES MELLITUS ASSOCIATED OVERACTIVE BLADDER SYMPTOMS.

Hypothesis / aims of study

To elucidate the differences in clinical efficacy of anticholinergics to manage the diabetes mellitus (DM) related overactive bladder (OAB) versus idiopathic OAB in Korean women

Study design, materials and methods

We conducted multicenter, prospective, parallel-group, open-label, 12 week study. Patients (20 ~ 65 years old women) suffered OAB symptom for over than 3 months were classified into DM OAB group and idiopathic OAB group. Changes in OABSS score, urgency, urge incontinence, frequency night, frequency on voiding diary, uroflowmetry, and PVR at the first visit (V1), week 4 (V2), and week 12 (V3) were compared.

Results

No significant difference was found between the baseline patient characteristics of DM OAB group and idiopathic OAB group. Treatment with solifenacin demonstrated improvement in urgency, urge incontinence, frequency night, frequency on voiding diary OABSS Total scores in both of between V1 and V2 and that between V1 and V3. And improvement in urgency, urge incontinence were significant between V2 and V3 in DM OAB group However, no significant changes were found in any other parameters. There were no significant differences between DM OAB group and idiopathic OAB group except urgency, urge incontinence in V2 (3.71 versus 2.28 and 0.47 versus 0.32).

Interpretation of results

Patients with solifenacin were well effectively improved urgency, urge incontinence, frequency night, frequency on voiding diary OABSS total scores.

Concluding message

Management of solifenacin were equally effective in both of diabetes mellitus (DM) diabetes mellitus (DM) related OAB and idiopathic OAB.

Parameters	DM OAB	idiopathic OAB	P-value
Patients (n)	66	135	
Age (years)	55.8±6.9	55.5±7.1	0.96
OABSS Total	5.23±2.4	5.01±2.2	0.53
Urgency	6.6±4.1	5.59±3.7	0.56
Urge incontinence	1.02±0.4	0.89±0.3	0.62
Frequency	8.61±2.4	8.82±2.5	0.88
Night Frequency	1.76±0.9	1.59±0.9	0.23
Qmax (ml/sec)	19.83±9.6	18.01±7.6	0.42
PVR (ml)	16.73±4.1	18.38±4.5	0.19

Parameters	V2		V3	
	DM OAB	idiopathic OAB	DM OAB	idiopathic OAB
OABSS Total	3.23±1.2*	3.16±1.4*	3.01±0.9†	2.89±1.1†
Urgency	3.71 ± 2.1*‡§	2.28 ± 1.7*:	2.09± 1.8 †	1.77 ± 0.9 †
Urge incontinence	0.47 ± 0.2*‡§	0.32 ± 0.1*:	0.23± 0.1†	0.27 ± 0.1†
Frequency	7.01±5.5*	5.98±3.4*	6.33±3.7†	5.70±2.3†
Night Frequency	1.36±0.1*	1.24±0.4*	1.15±0.4†	0.85±0.3†
Qmax (ml/sec)	15.26±6.5	15.14±6.4	13.86±6.7	12.76±6.3
PVR (ml)	27.43±18.1	29.97±19.4	32.74±14.4	36.36±17.3

*: p<0.05 V1 vs. V2, † : p<0.05 V1 vs. V3, ‡ : p<0.05 V2 vs. V3, § : p<0.05 Group I vs Group II

Disclosures

Funding: The authors have nothing to disclose. **Clinical Trial:** Yes **Public Registry:** No **RCT:** Yes **Subjects:** HUMAN **Ethics Committee:** each medical center's institutional review board **Helsinki:** Yes **Informed Consent:** Yes